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Many cancer patients use complementary alternative medicines (CAMs) but may not be aware of the potential risks. There are no
studies quantifying such risks, but there is some evidence of patient risk from case reports in the literature. A cross-sectional survey of
patients attending the outpatient department at a specialist cancer centre was carried out to establish a pattern of herbal remedy or
supplement use and to identify potential adverse side effects or drug interactions with conventional medicines. If potential risks were
identified, a health warning was issued by a pharmacist. A total of 318 patients participated in the study. Of these, 164 (51.6%) took
CAMs, and 133 different combinations were recorded. Of these, 10.4% only took herbal remedies, 42.1% only supplements and
47.6% a combination of both. In all, 18 (11.0%) reported supplements in higher than recommended doses. Health warnings were
issued to 20 (12.2%) patients. Most warnings concerned echinacea in patients with lymphoma. Further warnings were issued for cod
liver/fish oil, evening primrose oil, gingko, garlic, ginseng, kava kava and beta-carotene. In conclusion, medical practitioners need to be
able to identify the potential risks of CAMs. Equally, patients should be encouraged to disclose their use. Also, more research is
needed to quantify the actual health risks.
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The use of complementary alternative medicines (CAM) is well
documented (Ernst and Cassileth, 1999). These are either used on
their own (alternative) or in addition to conventional medicine
(complementary) (Zimmerman and Thompson, 2002). This is
particularly common in patients suffering from chronic disorders
such as cancers and their associated physical and psychological
problems. Depending on the definition and inclusion criteria
chosen, estimates range from 7 to 64% in the reported prevalence
of CAM use in cancer patients (Ernst and Cassileth, 1998). More
recent studies have reported an even higher prevalence of between
70 and 80% (Richardson et al, 2000; Bernstein and Grasso, 2001;
Ashikaga et al, 2002). The nature of CAMs used, for example,
vitamins and other supplements, herbal remedies, physical and
psychological treatments, also varies greatly (Risberg et al, 1998;
Richardson et al, 2000; Sparber et al, 2000; Bernstein and Grasso,
2001; Ashikaga et al, 2002).
Patients with chronic illnesses who seek alternative therapies are
likely to use conventional medicine regularly and simultaneously.
However, they may not always inform their doctor of the
concomitant use of alternative medicine. For instance, a study of
Eisenberg and co-workers in the US showed that 96% of
alternative-medicine users also sought a conventional medicine
provider for at least one medical condition. In all, 28%
used alternative medicine for the same medical condition, and
72% did not inform their physician (Eisenberg et al, 1993; Kessler
et al, 2001). The reasons for CAM use have been widely
investigated. Patients often wish to combine conventional and
CAM approaches to improve their quality of life, to counter side
effects, to achieve a sense of control and to match their life style
with their world view (Austin, 1998; Sparber et al, 2000; Kessler
et al, 2001).
However, the use of CAM and especially of herbal remedies and
supplements is not without problems. Unconventional cancer
therapies such as Laetrile, Essiac and coenzyme Q10 may not be
effective (Ernst and Cassileth, 1999). Furthermore, CAMs have
potentially dangerous side effects and interactions with conven-
tional treatments. For instance, garlic and cod liver oil have
anticoagulant effects (Fugh-Berman, 2000), and remedies acting on
the cytochrome P450 system such as St John’s wort, may interact
with hormones, antibiotics and chemotherapeutic agents (Izzo and
Ernst, 2001).
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lMany reviews of the potential dangers have been published, but
clinical accounts are mostly confined to individual case reports of
adverse events (Ernst, 1998). The purpose of this survey was to
prevent potential health risks, which CAM users might encounter.
We aimed to establish the type, frequency and pattern of herbal
medicine and supplement use in a sample of cancer patients and to
identify and quantify the potential for adverse side effects or drug
interactions with conventional medicines.
METHODS
We conducted a cross-sectional survey of patients attending the
outpatient departments at the Royal Marsden Hospital, a specialist
cancer centre using a multiple-choice questionnaire to estimate the
presence, frequency and purpose of herbal medicines and
supplement use. In addition, respondents were asked whether
they had discussed their CAM therapy with their medical
practitioners. The questionnaire was piloted on 5% of the sample,
and amended as necessary. The completed questionnaires were
returned to the Medicines Information Service at the Royal
Marsden Hospital pharmacy. There they were scrutinised for
potentially serious adverse effects or interactions with prescribed
medicines using the web-based and library resources. If the
potential for an adverse drug reaction or interaction was detected,
the pharmacist (CS) issued a health warning to the patient and
treating doctor or GP. The data were entered into a database and
analysed descriptively using SPSS version 10. Patients gave written
informed consent before participation in the study. The project
had received ethical approval from the Royal Marsden Hospital
Ethics Committee.
RESULTS
Of the 500 patients invited to participate, 318 (63.6%) agreed to
take part in the study, of whom 60.4% were female. As the study
was conducted immediately after consent had been obtained, it
was difficult to establish the reason for nonparticipation. However,
65.0% of the nonparticipants stated that the study did not apply to
them as they were not taking any CAMs.
Of the patients surveyed, 164 (51.6%) took herbal remedies and/
or food supplements. In all, 133 different substances and
combinations were recorded. Of these, 16 (9.8%) took CAM in
the form of homeopathic preparations. Patients took on average
1.8 (72.34) supplements; 40.9% took more than one substance
and three patients took 10 or more preparations, and 17 (10.4%)
only took herbal remedies, 69 (42.1%) only supplements and 78
(47.6%) a combination of both. Among the alternative remedies,
Echinacea, evening primrose oil, ginkgo, milk thistle and essiac
were most popular (Table 1a). Individual supplements included
vitamin C, E and a combination of vitamin A, C and E (ACE), cod
liver oil, selenium, beta-carotene, coenzyme Q10 and germanium.
However, the majority took either multivitamins or other
combinations, which were difficult to quantify in detail (Table 1b).
Half of all patients took CAMs for the nonspecific purpose of
improving their health or in order to fight cancer, rather than for a
specific indication such as boosting their immune system. Most
patients took the remedies according to their purported indication,
although many of the indications, particularly anticarcinogenic
effects, are unproven. Patients with haematological cancer aimed
to boost their immune system with echinacea. Patients with breast
cancer used cod liver oil for joint pain and evening primrose oil for
breast soreness or hormonal disturbances. Milk thistle was taken
to detoxify the liver, presumably to counter some side effects of
chemotherapy. One patient with lung cancer tried shark cartilage
that is supposed to inhibit angiogenesis. In all, 41 (25.0%) patients
took substances with psychoactive properties. However, 53
(32.3%) patients were not sure about the purpose of a remedy
taken. For further reference, the suggested indications for all the
listed remedies are listed in Appendix A.
The pharmacy issued health warnings for 20 (12.2%) patients
taking herbal medicines or supplements (Table 2a–c). Most
concerned the use of echinacea in patients with lymphoma. Owing
to its immune system-stimulating activity, Echinacea could have
interfered with corticosteroid and monoclonal antibody treatment
(Natural Medicines Comprehensive Database, 2003). Further
warnings were issued for cod liver/fish oil, evening primrose oil,
ginkgo and garlic, all of which have coumarinic constituents, as an
interaction with warfarin, aspirin and nonsteroidal anti-inflam-
matory drugs could lead to an increase in INR (Fugh-Berman,
2000; Natural Medicines Comprehensive Database, 2003). Patients
were informed of a potential interference of Siberian Ginseng with
antihypertensive therapy (Natural Medicines Comprehensive
Database). Kava kava is potentially hepatotoxic (Escher et al,
2001; Russmann et al, 2001), which has led to voluntary withdrawal
of all preparations from the UK market. We also issued a qualified
warning to one patient taking beta-carotene, who was known to be
an occasional smoker. Beta-carotene may increase the risk of
prostate and lung cancer in smokers through enhanced production
of beta-carotene oxidation metabolites if they are not neutralised
by other antioxidants such as vitamin C and E (Heinonen et al,
1998; Patrick, 2000). In addition, 18 (11.0 %) patients reported
taking supplements higher than the recommended doses. These
Table 1 (a) Alternative remedies taken (n¼166
a) (b) supplements and
supplement combinations taken (n¼324
a)
Remedy n %
(a)
Echinacea 35 21.1
Evening primrose oil 33 19.9
Ginkgo 16 9.6
Milk thistle 11 6.6
Essiac 10 6.0
Chinese remedies (except green tea) 7 4.2
Garlic 7 4.2
St John’s wort (Hypericum) 6 3.6
Arnica 5 3.0
Valerian 5 3.0
Bach flower remedies 4 2.4
Green tea 3 1.8
Kava Kava 3 1.8
Siberian Ginseng 3 1.8
Passion Flower 2 1.2
Aloe Vera 2 1.2
Indian remedies incl. turmeric and ginger 2 1.2
Laetrile (vitamin B17) 2 1.2
Panax Ginseng 2 1.2
Wild yam 2 1.2
Golden seal 1 0.6
Grape seed extract 1 0.6
Kelp 1 0.6
Mistletoe (Iscador) 1 0.6
Shark cartilage 1 0.6
Slippery elm 1 0.6
(b)
Vitamin C/E/combination ACE 53 16.4
Cod liver oil 34 10.5
Selenium 20 6.2
Beta-carotene 7 2.2
Coenzyme Q10 (Ubiquinone) 1 0.3
Germanium 1 0.3
Multivitamins 104 32.1
Other combinations 104 32.1
a40.9% of patients took more than one CAM.
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lTable 2 Warnings issued by (a) pharmacy: lymphoma (b) pharmacy: breast cancer (c) pharmacy: other cancers
Diagnosis CAM taken
Other
medication Concern Advice given
(a)
Non-Hodgkin
lymphoma
Echinacea Rituximab Stimulation of B lymphocytes which monoclonal antibodies are
targeting (Stimpel et al, 1984; Luettig et al, 1989)
Stop echinacea
Stimulation of phagocytosis
Increased activity and mobility of leucocytes.
Induction of macrophages to produce cytokines (TNF, IL-1,
interferon beta-2) (Stimpel et al, 1984; Luettig et al, 1989)
B-cell
lymphoma
Cod liver oil Warfarin Cod liver oil: increase of INR with high or changing doses
(Fugh-Berman, 2000)
Monitor INR
Evening primrose
oil
Sodium valproate Evening primrose oil: decrease of seizure threshold; decrease of
effectiveness of antiepileptic medication (Miller, 1989)
Discuss evening primrose oil
with doctor as unclear whether
Sodium valproate was taken for
epilepsy
Non-Hodgkin
lymphoma
Echinacea Echinacea: stimulation of immune system as above Stop both agents
Kava Kava Kava Kava: hepatotoxic (Escher et al, 2001; Russmann et al, 2001;
Brauer et al, 2003; Humberston et al, 2003)
Lymphoma not
specified
Echinacea Corticosteroids,
monoclonal
antibodies
Stimulation of immune system as above Stop echinacea
B-cell
lymphoma
Kava Kava,
Echinacea
Echinacea: stimulation of immune system as above Stop both agents
Kava Kava: hepatotoxic
Hodgkin’s
lymphoma
Echinacea Stimulation of immune system but no interactions with Hodgkin’s
disease yet reported
Avoid long-term use
(b)
Breast Ginseng royal jelly Bendrofluazide Ginseng: increases or decreases blood pressure (Natural Medicines
Comprehensive Database 2003)
Monitor blood pressure, be
aware of allergic potential of
royal jelly, patient had been
hospitalised with an asthma
attack shortly after use, unclear
whether related
Royal jelly: allergic reactions possible if history of asthma or atopy
(Leung et al, 1997; Thien et al, 1996)
Breast Siberian ginseng Antihypertensive
therapy
Siberian ginseng: increases or decreases blood pressure (Natural
Medicines Comprehensive Database, 2003)
Monitor blood pressure
Goldenseal
Germanium
Goldenseal: increases of blood pressure (Natural Medicines
Comprehensive Database, 2003)
Stop germanium
Germanium: case reports of renal failure, anaemia, neurological and
muscular problems (Tao and Bolger, 1992)
Breast Wild yam Oestrogenic effect (Aradhana et al, 1992) Stop wild yam
Breast Evening primrose
oil, Fish oil
Naproxen Both: increase INR (Brox et al, 1981; Natural Medicines
Comprehensive Database, 2003)
Report any sign of bleeding
Breast Kava Kava, Kava Kava: hepatotoxic Stop kava kava
Breast Cod liver oil Ibuprofen Increases INR in high doses (Brox et al, 1981; Natural Medicines
Comprehensive Database, 2003)
Report any sign of bleeding
Breast Beta-carotene Increases risk of lung and prostate cancer in smokers (The Alpha-
Tocopherol, Beta Carotene Cancer Prevention Study Group 1994;
Heinonen et al, 1998; Patrick, 2000)
Stop beta-carotene
Breast Milk thistle,
Goldenseal
Paclitaxel Both potentially decrease Paclitaxel metabolism (Zuber et al, 2002;
Daly and King, 2003; Natural Medicines Comprehensive Database,
2003)
Stop both agents
(c)
Prostate Ginkgo cod liver oil Diclofenac Codliver oil: antithrombotic effect, increases INR (Brox et al, 1981;
Natural Medicines Comprehensive Database, 2003)
Report any sign of bleeding
Ginkgo reduces platelet adhesiveness and platelet count, increases
INR (Fugh-Berman, 2000)
Ovarian Coenzyme Q10
(ubiquinone)
Warfarin Coenzyme Q10: reduces anticoagulant properties of warfarin, has
vitamin K like effects
Unable to assess safety of
combination, therefore not
recommended
Milk thistle Milk thistle: inhibits warfarin metabolism (CYP2C9) (Heck et al,
2000; Daly and King, 2003; Natural Medicines Comprehensive
Database, 2003)
Oesophageal Garlic Aspirin,
Omeprazole
May increase INR, increased risk of gastro-intestinal haemorrhage
(Fugh-Berman, 2000)
Report any sign of bleeding
Testicular Ginkgo, Garlic,
Codliver oil
Aspirin All may increase INR (Brox et al, 1981; Fugh-Berman, 2000; Natural
Medicines Comprehensive Database, 2003)
Report any sign of bleeding
Endometrial Milk thistle Doxorubicin Potentially decreases doxorubicin metabolism (Kivisto et al, 1995) Stop milk thistle
Ovarian Laetrile (apricot) Safety concern because of cyanide contents (Natural Medicines
Comprehensive Database, 2003)
Advised of risk and discouraged
use
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lincluded: vitamin C (5), vitamin E (4), multivitamins (3), zinc (3),
calcium (2), cod liver oil (2) and one of each of the following:
selenium, magnesium, glucosamine, germanium, folic acid, tomato
tablets and beta-carotene.
Only 46.3% using CAMs had discussed these with a health-care
professional involved in their conventional treatment, and
reported that 82.9% of the conventional practitioners gave a
favourable or neutral response. Conversely, only 56 (34.1%) had
consulted an alternative practitioner. Of these 78.6% had discussed
their conventional medicines.
DISCUSSION
Our survey confirms that there is a high prevalence of herbal
medicine and supplement use in cancer patients. A substantial
proportion of patients used remedies that have the potential to
cause serious adverse reactions or drug interactions. To our
knowledge, this survey is the first attempt to identify these
potential risks for an actual sample of cancer patients before
adverse events have emerged. However, we do not know how these
potential risks translate into actual events, and research is required
to establish the frequency and seriousness of such side effects and
drug interactions. As this study was based on voluntary participa-
tion and CAM users seemed to be more likely to participate, we
may have overestimated CAM use. However, even if all non-
participants did not use any form of alternative remedy, the
proportion of CAM users would still be 33%. Nonparticipation did
not affect the risk estimates, that is, the main area of interest in this
study. It was also difficult to draw a clear line between remedies
and supplements as these overlap and many patients took
combinations.
Although most patients had discussed their use with a
health-care professional, there remained a considerable potential
for harmful effects. There may be different reasons for this.
Medical practitioners may not have the expert knowledge required
to deal with the large number of potential risks or may not
have the time to do so in routine outpatient clinics. Also, patients
may not accept their doctors’ opinion and may argue that
conventional cancer treatment can be equally toxic. Thus
patients may require more education on the benefits of CAMs
and their risk management. For instance, patients need to know
that for some vitamins, effectiveness is only established when
taken in fruit and vegetables but not as supplements (Moertel
et al, 1985) or that effectiveness of supplements may be confined to
specifically selected populations (Blot et al, 1993; Russell, 2000).
They also need to know that supplements may be associated
with adverse events including bleeding and liver failure (Palmer
et al, 2003) or fail to work, for example, high dose vitamin C
(Creagan et al, 1979). Only recently, the UK Food Standards
Agency has reduced the safe upper limit for many supplements
(Food Standards Agency, 2003). Also, the potential for CAM
to interact with drugs given during diagnostic procedures or
radiotherapy needs to be recognised. For instance, kelp can
interact with contrast agents containing iodine, as used in bone
and thyroid scanning (Eliason, 1998). Antioxidants binding free
radicals or remedies increasing photosensitivity may interfere with
radiotherapy (Ernst, 1998).
Our survey highlights the importance for conventional health-
care professionals to discuss CAM use with their patients.
Clinicians need to be aware of CAM-induced side effects or
interactions and identify hazards, advising patients accordingly
and avoiding uncritical encouragement of potentially harmful
use. Otherwise, prescribers may expose themselves to criticism
and possibly litigation (Cohen and Eisenberg, 2002). Equally
patients should be encouraged to disclose information about
CAMs to health-care professionals. Such discussions need to be
conducted sensitively in order to avoid alienating patients who
may feel that they have not been taken seriously or have been
criticised for using CAM. Also, given that about one-third of
the remedies used had psychotropic effects, the question of
whether CAM users have special psychological needs should be
explored.
Also, research on CAMs and their interactions with conventional
medicines needs to keep pace with the development of new
cancer therapies. Although in randomised controlled trials the
proportion of CAM users should be equal in each trial arm, the
trial outcome could theoretically be influenced if a CAM
specifically interacts with the trial agent but not with the control
medication/placebo.
Doctors will need to devote time to discussing CAM use in
outpatient clinics, although the complexities of side effects and
interactions may require clinics that are run jointly with a local
medicines information and toxicology services that provide access
to and interpretation of herbal formularies, reference texts and
web-based resources such as Natural Medicines Comprehensive
Database (2003) (naturaldatabase.com) and Longwood Herbal
Task Force (www.mcp.edu/herbal). Also, pharmacists have a key
role in updating physicians and sharing important information
gathered from patients with other health-care professionals
(Klepser and Klepser, 1999). Service models need to be designed
and tested to meet this challenge.
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Appendix A
Postulated effects of CAMs (Natural Medicines Comprehensive
Database, 2003; Physician Desk Reference for Herbal Medicines,
2000) are given in Tables A1–A4.
Table A1 Suggested indication: anticarcinogenic
Remedy
Approved by German
regulatory authority
(Commission E) Selected other/unproven Suggested mechanism of action
Coenzyme Q10
(ubiquinone)
— Inhibition of cancer growth; prevention of
cardiotoxicity associated with anthracyclins
Antioxidant
Beta-carotene, vitamin
C and E and ACE
— Inhibition of cancer growth; stimulation of
immune system
Antioxidants; Vitamin c and E and ACE can neutralise
carcinogenic metabolites of beta-carotene
Essiac — Inhibition of cancer growth; stimulation of
immune system
Burdock root: prevention of angiogenesis and inhibition
of tumour neovascularisation (also contains: sheep
sorrel, rhubarb and slippery elm)
Goldenseal — Inhibition of cancer growth Berberine: (isoqinolone alkaloid): inhibition of tumour
promoters, inhibition of cancer cells; neutropenia
resulting from radio- and chemotherapy gastritis, gastric
ulcers and gallbladder disease, diarrhoea
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lGreen tea — Cancer prevention; inhibition of cancer
growth; nausea and vomiting; diarrhoea;
caries prevention
Polyphenols: antioxidant
Laetrile (Vitamin B17,
Apricot kernels)
— Cancer prevention Amygdalin: cytostatic through cyanide release; balance
of vitamin deficiency
Mistletoe (Iscador) — Cancer prevention and treatment;
stimulation of immune system
Viscotoxins and viscumin (mistletoe lectin):
modification of intracellular protein syntheses,
stimulation of cytokine production, inhibition of tumour
colonisation, induction of cell necrosis (Ernst and
Cassileth, 1999)
Selenium — Cancer prevention; inhibition of cancer
growth
Antioxidant
Shark cartilage — Cancer prevention; inhibition of cancer
growth
Sphyrnastatin 1 and 2: prevention of angiogenesis and
inhibition of tumour neovasculariastion
Turmeric Dyspeptic complaints; loss
of appetite
Cancer prevention; inhibition of cancer
growth
Curcuminoids: antioxidant, alteration of cancer cell
metabolism, cytotoxicity against human chronic myeloid
leukaemia
Table A1 Continued
Remedy
Approved by German
regulatory authority
(Commission E) Selected other/unproven Suggested mechanism, of action
Table A2 Suggested indication: immune-stimulation
Remedy Commission E approved Selected unproven other
Arnica Topical use: respiratory, oral and cutaneous infections; blunt injuries; boost immune system —
Echinacea Respiratory, oral and urinary tract infections; wounds and burns; boost immune system —
Table A3 Suggested indication: psychoactive
Remedy Commission E approved Selected unproven other
Bach flower remedies — Nervousness, tension
Ginkgo Symptomatic relief of organic brain dysfunction; intermittent claudication; vertigo and
tinnitus of vascular origin
Boost immune system
Kava Kava Nervousness and insomnia —
Panax Ginseng Lack of stamina and fatigue —
Siberian Ginseng Lack of stamina; risk of infections —
Passion flower Nervousness and insomnia —
St John’s wort (Hypericum) Anxiety; depressive moods; topical use; skin inflammations, blunt injuries, wounds and
burns
—
Valerian Nervousness and insomnia —
Table A4 Suggested indications: other
Remedy Commission E approved Selected unproven other
Evening primrose
oil
— Premenstrual problems and menopausal hot flashes; mastalgia neurodermitis
and atopic eczema
Wild yam — Dysmenorrhoea and cramps; postmenopausal symptoms, e.g. vaginal dryness;
rheumatic conditions; gallbladder colic
Cod liver oil Arthritis; prevention of coronary heart
disease; vision
Cancer prevention; inhibition of cancer growth; hypertension;
hypertriglyceridaemia
Kelp Regulation of thyroid function
Garlic Arteriosclerosis; hypertension raised
level of cholesterol (hyperlipidaemia)
—
Ginger Loss of appetite; travel sickness;
dyspeptic complaints
—
Milk thistle Dyspeptic complaints Liver and gallbladder complaints
Slippery elm — Gastritis gastric and duodenal ulcers
Grape seed — Venous diseases Blood circulation disorders
Aloe vera — Wound healing
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